Breaking Finance News

finnCap announced Premaitha Health Plc (LON:NIPT), upholding its stock price target at 20.00GBX today

Just yesterday Premaitha Health Plc (LON:NIPT) traded -2.04% lower at 8.13GBX. Premaitha Health Plc’s 50-day moving average is 9.03GBX and its 200-day moving average is 9.40GBX. The last stock price is down -14.03% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.03% over the same time period. 205,970 shares of NIPT traded hands, down from an average trading volume of 689,201

In a report released on 11/29/2016 finnCap hold steady the stock price target of Premaitha Health Plc (LON:NIPT) from 20.00GBX to 20.00GBX reporting a possible upside of 1.46%.

Previously on 11/21/2016, finnCap released a statement about Premaitha Health Plc (LON:NIPT) held steady the target price at 20.00GBX. At the time, this indicated a possible upside of 1.25%.

Recent Performance Chart

Premaitha Health Plc (LON:NIPT)

Premaitha Health Plc has 52 week low of 6.50GBX and a 52 week high of 21.50GBX and has a market capitalization of 0 GBX.

In addition to finnCap reporting its stock price target, a total of 2 brokerages have issued a ratings update on the company. The average stock price target is 22.00GBX with 0 brokerages rating the stock a strong buy, 1 brokerage rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Premaitha Health Plc (LON:NIPT)

Premaitha Health PLC is engaged in molecular diagnostics business for research into, and the development and commercialization of gene analysis techniques for pre-natal screening and other clinical applications in the early detection, monitoring and treatment of disease. The Company's product, the IONA test is a non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer a regulated non-invasive prenatal test in-house. The IONA test estimates the risk of a fetus having Down's syndrome or other serious genetic diseases. The risks that fetus may be affected with include Trisomy 21 (Down's syndrome), Trisomy 18 (Edwards' syndrome), Trisomy 13 (Patau's syndrome) and Fetal sex determination optional. The analysis is performed on cell-free placental deoxyribonucleic acid (DNA) from a maternal blood sample, with test results available in three days turnaround time. The Company operates in the United Kingdom and Rest of the World.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *